Konkomitant Kemoradyoterapi Prensipleri
Özet
Kanser tedavisinde multidisipliner yaklaşımlar kapsamında lokal cerrahi ve lokorejyonel radyoterapinin (RT) yanı sıra sistemik kemoterapi (KT) kombinasyonları, genel sağkalımı ve lokal kontrolü artırmak adına kritik rol oynamaktadır. Eşzamanlı kemoradyoterapi (KRT) uygulamaları, mikrometastatik hastalıklarla mücadele etmeyi ve normal dokuları korurken tümör kontrol olasılığını simgeleyen terapötik indeksi optimize etmeyi hedefler. Steel ve Peckham'ın çalışmalarına dayanan bu yaklaşımlar; bağımsız toksisite profillerinden yararlanmayı, normal doku koruyucularını (amifostin gibi) kullanmayı, uzamsal işbirliği sağlamayı ve doğrudan sitotoksik iyileşmeyi amaçlar. Biyolojik ve uzamsal işbirliği sayesinde, özellikle hipoksik veya radyasyona intrensek dirençli tümör hücre alt popülasyonlarının ortadan kaldırılması kolaylaşır. İlaç-radyasyon etkileşimleri; DNA hasarının artırılması, DNA tamir mekanizmalarının inhibe edilmesi, hücre döngüsünün radyosensitif fazlarda (G2/M) durdurulması ve tümör repopülasyonunun engellenmesi gibi temel biyolojik mekanizmalar üzerinden yürütülür. Klinikte sıklıkla başvurulan antimetabolitler (5-FU, gemsitabin), alkilleyici ajanlar (temozolomid, mitomisin C), platin türevleri (sisplatin), mikrotübül hedefleyiciler (taksanlar) ve topoizomeraz inhibitörleri (irinotekan, etoposid) farklı faz özgüllükleriyle radyasyonun antitümör etkinliğini önemli ölçüde artırır. Kişiselleştirilmiş onkoloji çağında bu kombine rejimlerin optimizasyonu, biyobelirteçlerin kullanımı ve hastaya özgü terapötik indeksin en üst düzeye çıkarılması kanser morbidite ve mortalitesi ile mücadelede temel dayanaktır.
In cancer management, multidisciplinary approaches combining local surgery and locoregional radiotherapy (RT) with systemic chemotherapy (KT) play a critical role in enhancing overall survival and local control. Concurrent chemoradiotherapy (KRT) strategies aim to eradicate micrometastatic disease and optimize the therapeutic index, which balances the probability of tumor control against normal tissue toxicity. Based on the theoretical concepts of Steel and Peckham, these combined approaches focus on exploiting non-overlapping independent toxicities, integrating normal tissue protectors like amifostine, achieving spatial cooperation, and driving cytotoxic enhancement. Spatial and biological cooperation facilitate the elimination of tumor cell subpopulations that are either hypoxic or intrinsically resistant to radiation. Drug-radiation interactions operate through fundamental biological mechanisms, including the amplification of radiation-induced DNA damage, inhibition of DNA repair pathways, cell cycle arrest in radiosensitive phases (G2/M), and suppression of accelerated tumor repopulation. Clinically utilized chemotherapeutic classes—such as antimetabolites (5-FU, gemcitabine), alkylating agents (temozolomide, mitomycin C), platinum compounds (cisplatin), microtubule-targeting agents (taxanes), and topoisomerase inhibitors (irinotecan, etoposide)—significantly bolster the antitumor efficacy of radiation through distinct phase-specific mechanisms. In the era of personalized oncology, optimizing these combined regimens through robust biomarkers and tailoring the therapeutic ratio remains the cornerstone of overcoming cancer-related morbidity and mortality.
Referanslar
C Heidelberger, NK Chaudhuri, P Danneberg, et al.: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 179:663-666 1957.
TA Rich, RC Shepard, ST Mosley: Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol. 22:2214-2232 2004.
GG Steel, MJ Peckham: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 5:85-91 1979.
JR Kouvaris, VE Kouloulias, LJ Vlahos: Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 12:738-747 2007
SM Bentzen, PM Harari, J Bernier: Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol. 4:172-180 2007
HR Withers: Four R’s of radiotherapy. Adv Radiat Biol. 5:241-247 1975
T Terasima, LJ Tolmach: Changes in x-ray sensitivity of HeLa cells during the division cycle. Nature. 190:1210-1211 1961
WK Sinclair, RA Morton: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res. 29:450-474 1966
H Choy, FF Rodriguez, S Koester, et al.: Investigation of taxol as a potential radiation sensitizer. Cancer. 71:3774-3778 1993
RB Tishler, CR Geard, EJ Hall, PB Schiff: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 52:3495-3497 1992
RB Tishler, PB Schiff, CR Geard, EJ Hall: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 22:613-617 1992
CJ McGinn, TJ Kinsella: The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol. 19:21-28 1992
PL Olive: Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine. Br J Cancer. 71:529-536 1995
L Milas, N Hunter, KA Mason, et al.: Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol. 34:409-412 1995
P Hentosh: Induction and repair of DNA damage in gamma-irradiated human lymphoblasts: irradiation in the presence and absence of misonidazole. Radiat Res. 115:436-447 1988
S Dische: Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother Oncol. 3:97-115 1985
L Galluzzi, I Vitale, SA Aaronson, et al.: Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25:486-541 2018
VT DeVita, Chu E: A history of cancer chemotherapy. Cancer Res. 68:8643-8653 2008
MJ O’Connell, JA Martenson, HS Wieand, et al.: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 331:502-507 1994
N Sawada, T Ishikawa, F Sekiguchi, et al.: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 5:2948-2953 1999
M Endo, N Shinbori, Y Fukase, et al.: Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5’-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer. 83:127-134 1999
Wang X, Zhao DB, Yang L, et al.: S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study. Br J Cancer. 118:338-343 2018
PY Chun, Feng FY, AM Scheurer, et al.: Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res. 66:981-988 2006
Z Symon, M Davis, CJ McGinn, et al.: Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys. 53:140-145 2002
Chen M, AM Hough, TS Lawrence: The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol. 45:369-374 2000
TS Lawrence, A Eisbruch, CJ McGinn, et al.: Radiosensitization by gemcitabine. Oncology (Williston Park). 13:55-60 1999
CJ McGinn, MM Zalupski, I Shureiqi, et al.: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 19:4202-4208 2001
N Adhikari, A Biswas, A Gogia, et al.: A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome. J Neurooncol. 139:153-166 2018
Wang Y, Liu S, Wei X, et al.: Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report. Onco Targets Ther. 11:4733-4738 2018
Wang JC: DNA topoisomerases. Annu Rev Biochem. 65:635-692 1996
BA Teicher, Chen V, C Shih, et al.: Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res. 6:1016-1023 2000
M Bischof, P Huber, C Stoffregen, et al.: Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases. Int J Radiat Oncol Biol Phys. 57:289-292 2003
M Bischof, KJ Weber, J Blatter, et al.: Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys. 52:1381-1388 2002
FE Adair, HJ Bagg: Experimental and clinical studies on the treatment of cancer by dichlorethylsulphide (mustard gas). Ann Surg. 93:190-199 1931
MC Heinrich, ME Hoatlin, AJ Zigler, et al.: DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood. 91:275-287 1998
K Sugiyama, M Shimizu, T Akiyama, et al.: UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Int J Cancer. 85:703-709 2000
M De Ridder, G Van Esch, B Engels, et al.: Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway. Bull Cancer. 95:282-291 2008
JA Ajani, KA Winter, LL Gunderson, et al.: Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 299:1914-1921 2008
ND Nigro, VK Vaitkevicius, B Considine Jr: Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 17:354-356 1974
Amarasingh S, Macleod MR, Whittle IR. What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma. J Neurooncol. 2009;91:117–125.
Amarasingh S, Macleod MR, Whittle IR. What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma. J Neurooncol. 2009;91:117–125.
Soloway MS, Morris CR, Sudderth B. Radiation therapy and cis-diammine-dichloroplatinum (II) in transplantable and primary murine bladder cancer. Int J Radiat Oncol Biol Phys. 1979;5:1355–1360
Amorino GP, Freeman ML, Carbone DP, et al. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys. 1999;44:399–405.
Behmand B, Marignier JL, Mostafavi M, et al. Radiosensitization of DNA by cisplatin adducts results from an increase in the rate constant for the reaction with hydrated electrons and formation of Pt(I). J Phys Chem B. 2015;119:9496–9500.
Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol. 2006;16:2–9
Ryu S, Gabel M, Khil MS, et al. Estramustine: a novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys. 1994;30:99–104.
Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8:2086–2095.
